GSK files for U.S. approval of new diabetes drug
LONDON (Reuters) - GlaxoSmithKline said on Monday it had filed for U.S. approval of its new once-weekly diabetes drug albiglutide and would make a similar submission shortly in Europe as it vies for a share of a crowded market. Albiglutide belongs to the same class of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca's Amylin unit. The submission by GSK, Britain's biggest drugmaker, was in line with its plan to seek regulatory approval for the new product in 2013. ...
Source: news.yahoo.com
No comments:
Post a Comment